Latest Advances in AML Treatment from ASCO 2025: Exploring Oral Regimens and Comparative Effectiveness
Amer Zeidan, MBBS, discusses how the future of acute myeloid leukemia (AML) treatment is shifting toward all-oral combination therapies like decitabine-cedazuridine plus venetoclax, which could become a new standard of care by reducing patient clinic burden while maintaining efficacy comparable to current intravenous regimens.
Episodes
June 30th 2025EP. 1: Unmet Needs and Emerging Trends in AML: ASCO 2025 Insights
A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 mutations and MECOM rearrangements, while emerging trends focus on combination therapies (doublets, triplets, quadruplets), the shift toward more convenient oral therapies, increased emphasis on minimal residual disease negativity as an end point, and expanded transplant eligibility for older patients aged into their mid to late 70s.
July 7th 2025EP. 2: All-Oral AML Therapy: Decitabine-Cedazuridine Plus Venetoclax
A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall survival in older, unfit AML patients, representing a potential new standard of care that eliminates the need for intravenous infusions and significantly reduces clinic time burden while serving as a backbone for future oral combination therapies.
